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Abstract
Phospholipase D3 (PLD3) is a non-classical, poorly characterized member of the PLD superfamily of signaling enzymes. PLD3
is a type II glycoprotein associated with the endoplasmic reticulum, is expressed in a wide range of tissues and cells, and
undergoes dramatic upregulation in neurons and muscle cells during differentiation. Using an in vitro skeletal muscle
differentiation system, we define the ER-tethering mechanism and report that increased PLD3 expression enhances
myotube formation, whereas a putatively dominant-negative PLD3 mutant isoform reduces myotube formation. ER stress,
which also enhances myotube formation, is shown here to increase PLD3 expression levels. PLD3 protein was observed to
localize to a restricted set of subcellular membrane sites in myotubes that may derive from or constitute a subdomain of the
endoplasmic reticulum. These findings suggest that PLD3 plays a role in myogenesis during myotube formation, potentially
in the events surrounding ER reorganization.
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Introduction
Myogenesis is a highly complex, multi-tiered, cell-cell fusion
event. Myoblasts, the immature muscle cells, proliferate until they
receive intra- and extra-cellular cues to withdraw from the cell
cycle, initiate muscle-specific gene expression and fuse together to
form nascent myotubes. These nascent myotubes then continue to
increase in size and nuclei number by fusing to more myoblasts
until they eventually form mature myofibers [1].
During differentiation, myoblast/myotubes make significant
changes to their membrane systems to form muscle-specific
organelles. The Golgi apparatus disperses into Golgi fragments
that associate with myonuclei for localized export of proteins
producedbydifferentnuclei[2,3,4].Smoothendoplasmicreticulum
(ER) reorganizes itself to form the sarcoplasmic reticulum (SR),
which holds and releases calcium for muscle relaxation and
contraction [reviewed in 5]. The plasma membrane, called the
sarcolemma, forms specialized invaginations called transverse (T)
tubules, an extensive membrane system with lipid and protein
compositions distinct from the sarcolemma [6]. The T-tubules
function totransfer actionpotentialstotheSR,eventuallyleadingto
muscle contraction.
Expression profiling of differentiating C2C12 myoblasts revealed
upregulation of Phospholipase D3 (PLD3) during myogenesis [7].
PLD3 is a lesser known family member of the PLD superfamily, a
family of phospholipases found in organisms from bacteria to
mammals. The extensively studied classical mammalian PLDs,
PLD1 [8] and PLD2 [9] play vital roles in vesicle trafficking and
fusion events in a number of cellular activities by producing
phosphatidic acid from phosphatidylcholine [10,11,12,13,14,15].
Other members of the PLD superfamily have been shown to be
involved in fusion events. Spo14, the yeast PLD homolog, is
required for the fusion of the prospore membrane [16], and
mammalian and drosophila mitoPLD participate in mitochondrial
fusion and fission [17,18,19].
PLD3 has not been well-characterized, in part due to its
divergence from the classical PLDs such as mammalian PLD1 [8]
and PLD2 [9], which function enzymatically via the action of a
pair of HxKxxxxD/E ‘‘HKD’’ split-catalytic domains that define
members of the PLD superfamily [20]. PLD3 also has a pair of
HKD domains, however neither canonical activity nor substrate
have been identified for it [21,22]. PLD3’s closest homolog is the
K4L protein found in vaccinia virus. Little can be inferred from
the homologous relationship with the vaccinia virus K4L protein
because vvK4L is not critical for the viral life cycle and no in vivo
function has been identified for it [23]. In vitro studies have
implicated vvK4L in nicking and joining of viral DNA [24], but
because this putative nuclease and repair activity is not required
for viral growth in tissue culture or in mice, it is presumably
redundant in those settings. The closest homolog of PLD3 and
vvK4L with a known function is the vaccinia virus F13L protein,
which is required for efficient viral cell-cell spreading by wrapping
intracellular virions in trans-Golgi or endosomal membranes
[23,25,26]. Like other PLDs, F13L requires an intact HKD
domain for activity [25,26], and the function performed by F13L is
blocked by 1-butanol, a crude chemical inhibitor of classic PLD
activity, but not by 2-butanol, a control alcohol that does not block
classic PLD activity, suggesting that F13L has PLD-like activity.
However, overexpression of PLD1 does not rescue F13L-deficient
virions [25], suggesting that the role(s) of F13L is more complex
than to simply produce PA in the Golgi or other endosomal
membranes. F13L has also been suggested to be a broad spectrum
lipase with phospholipase A and phospholipase C activities [25].
PLD1 and PLD2 localize to membrane structures via their PX
or PH domains [27]. PLD3 does not encode a PX or PH domain,
but has been shown to localize to the ER as a transmembrane
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at the N-terminus or a potential prenylation site at the C- terminus
[22], although these have not examined experimentally.
Expression studies have revealed that in addition to becoming
upregulated during myogenesis, PLD3 also increases in expression
in brain and neural tissues during neural differentiation [21,22].
These findings suggest that PLD3 may be generally involved in
cellular differentiation events. PLD3 has also been implicated in
sensing oxidative stress [28], which can impact differentiation
events such as myogenesis [29]. In the work we describe here, we
find that an increase in PLD3 expression facilitates myoblast
differentiation, whereas expression of a dominant-negative PLD3
mutant allele delays differentiation. We hypothesize that this may
be through the sensing of ER stress since PLD3 expression
increases as a consequence of exposure to agents that cause ER
stress and are known to promote myogenic differentiation [30].
These are the first functions found for PLD3, and in particular in
myoblast differentiation.
Materials and Methods
Cell culture and differentiation
C2C12 myoblasts [7] and NIH 3T3 fibroblasts [8] were
maintained in a humidified incubator containing 5% CO2 at 37uC
and grown in DMEM supplemented with 10% fetal bovine serum
(FBS), henceforth known as proliferation media (PM). To induce
myogenic differentiation, C2C12 myoblasts were grown, until
confluent, in proliferation media. Once confluent, the myoblasts
were switched from PM to differentiation media (DM), which was
DMEM supplemented with 2% horse serum (HS).
Plasmid transfection and infection
All DNA transfections, except viral packaging cell transfections,
were conducted using Lipofectamine and Plus reagents (Invitro-
gen) and 1 mg of DNA following the manufacturer’s instructions.
For infections, Plat-E [31] cells were transfected using calcium
phosphate. 48 hours after transfection, viral supernatants were
collected. Cells were infected by centrifuging the cells for 1 h at
1800 RPM in the collected viral supernatant supplemented with
8 mg/mL polybrene. 48 hours after infection, the cells were
selected with puromycin.
An open reading frame for human PLD3 was amplified from a
cDNA pool, subcloned into pcDNA3, and verified by DNA
sequencing. PLD3 was subcloned into additional vectors as
described; plasmids described in this report and additional details
regarding cloning will be provided upon request.
Quantitative PCR
C2C12 myoblasts were allowed to differentiate for 6 days as stated
above with cell pellets collected on a daily basis for the duration of the
experiment. RNA was extracted from differentiating myoblasts using
the RNeasy mini kit (Qiagen), following the manufacturers directions.
1 ng of total RNA was used for reverse transcription and amplification
using the HotStart Sybr green one-step qRT-PCR mastermix
kit (USB) and primers specific for PLD3 (FWD 59 CTGAG-
GAACCGGAAGCTGT REV 59 GGAAAGGGGTGGTCCTGA)
and GAPDH (FWD 59 TGGAGAAACCTG CCAAGTATG; REV
59 GTTGAAGTCGCAGGAGACAAC).
Cell lysis and Western Blot analysis
Cells were washed in PBS, lysed in modified RIPA buffer
(50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 150 mM NaCl, 1%
Na-deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM EGTA 0.5%
CHAPS) supplemented with a protease inhibitor cocktail (Roche),
and centrifuged at 3000 rpm for 10 min to remove nuclei and
cellular debris. The supernatants were then added to 26 sample
buffer containing 8 M urea followed by protein separation on 8–
15% SDS PAGE gels and transfer onto nitrocellulose membrane.
Membranes were blocked with 1% casein in TBS followed by
incubation with the appropriate primary antibodies in 1% casein
in TBST. Following the primary antibody incubation, membranes
were then washed, three times for 5 min each in TBST followed
by a one hour incubation with the appropriate secondary
antibodies conjugated with either the Alexa 680 (Invitrogen) or
IR Dye 800 (Rockland) fluorophores in 1% casein in TBST for
one hour. The membranes were then washed 3 times for 5 min
each in TBST followed by a 5 min wash in PBS and scanned using
an Odyssey Infrared Scanner (LI-COR) to visualize the protein
bands.
Immunofluorescence microscopy
Cells were seeded onto coverslips with or without collagen.
When ready, cells were washed 3 times in PBS and then fixed in
4% formaldehyde for 10 min. The cells were then blocked and
permeablized in blocking buffer (5%BSA and 5% normal goat
serum diluted in PBS) with 0.1% saponin for 1 hour followed by a
one-hour incubation in primary antibodies diluted in blocking
buffer. Afterwards, the cells were then washed with PBS 36 for
5 minutes each and incubated for one hour in secondary
antibodies and DAPI diluted in blocking buffer. The coverslips
were mounted on to slides with Vector Mount and visualized by
confocal microscopy using either a Zeiss LSM 510 Meta or a Leica
SP-2 microscope.
Anti-human PLD3 antisera was generated in rabbits against the
peptide YQELKVPAEEPANELPM (amino acids 7–23) as
immunogen and affinity-purified. The antisera detected recombi-
nant PLD3 expressed in HeLa cells both in western blots and in
immunofluorescent experiments. However, there also appeared to
be some residual non-specific immunoreactivity, so the antisera
was used only for western blot analysis. A second antisera was
generated against the peptide PRFYDTRYNQETPMEIC (amino
acids 265–282) but had inferior sensitivity and specificity. Anti-
KDEL antibody and other antisera were from Abcam.
Transient ER stress
Proliferating myoblasts were grown to confluency in PM and
treated with DMSO, Brefeldin-A (2 mM), tunicamycin (2 mg/ml),
thapsigargin (1 mM), calcium ionophore A23187 (10 mM), or
dithiothreitol (1 mM) for 30 minutes to one hour. The cells were
washed twice in warm PBS and immediately induced to
differentiate by incubating the cells in DM supplemented with
insulin (50 nM), changing the media daily for the duration of the
experiment.
Differentiated cells prepared on gelatin-coated coverslips were
treated as above or with amphotericin B (25 mg/ml), or wortmanin
(10 mM) for 4 hours, followed by fixation and confocal imaging.
Statistical methods description
Statistical analyses were performed using Student’s t-test, one-
way ANOVA, and Tukey post-hoc.
Results
PLD3 protein expression increases during C2C12
myogenic differentiation
A prior microarray study had reported that PLD3 mRNA
expression increases in C2C12 myoblasts during differentiation
[7], which we confirmed in preliminary studies by performing
PLD3 in Myotube Formation
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myoblasts (Fig. 1A). We then extended this finding by examining
whether protein levels similarly increased during differentiation.
Whole cell lysates were collected from C2C12 myoblasts and
analyzed by western blot analysis, which revealed that PLD3
protein expression levels increased along with mRNA expression
during C2C12 myoblast differentiation (Fig. 1B). The PLD3
mRNA levels reached maximal expression at day 4 post-induction
of differentiation (Fig. 1A), while the protein levels strongly
increased on day 3 and persisted thereafter through day 8 (Fig. 1B).
The PLD3 transmembrane domain targets PLD3 to the ER
A prior study had reported localization of PLD3 to the ER and
hypothesized that it might be anchored there via a potential N-
terminal transmembrane domain starting at amino acid 38 [21].
To test the role of the putative N-terminal signal sequence and
transmembrane domain, C-terminally-Myc-tagged mutants were
constructed by PCR-based deletion in which either the N-terminal
amino acids 1–37(D1–37) or 1–60 (D1–60) or the transmembrane
region amino acids 37–60 (D37–60) were removed (Fig. 2A).
NIH3T3 cells were transfected with the constructs and immuno-
stained using an anti-Myc antibody to detect the PLD3 mutants
and an anti-KDEL antibody to detect the ER. Wild-type (full-
length) PLD3 co-localized with the ER (Fig. 2B) consistent with the
prior report [21], as did the mutant that retained its transmem-
brane region, PLD3 D1–37-myc, whereas the mutant proteins
lacking the transmembrane region (D1–60 and D37–60) did not,
exhibiting instead ubiquitous cytoplasmic localization. These
results suggested that the transmembrane region is responsible
for PLD3 localization to the ER and constitutes the minimal
element required.
To confirm that the transmembrane domain directed PLD3
localization, constructs fusing the relevant N-terminal fragments of
PLD3 to EGFP or YFP were constructed and analyzed as above.
The fusion proteins containing the transmembrane domain, PLD3
1–60-YFP and 37–60-YFP, localized to the ER (Fig. 2C), where as
the construct containing only the N-terminal amino acids prior to
the transmembrane domain (PLD3 1–37-GFP) did not, instead
showing a diffuse localization throughout the cell. These results
confirm that the transmembrane domain targets PLD3 to the ER
and anchors it there.
PLD3 moves from the ER to ER-associated vesicular-like
structures or ER subdomains in C2C12 myotubes
Since the localization pattern of a protein in proliferating
fibroblasts does not necessarily accurately model its localization in
specialized cells, we next set out to examine PLD3 localization in
myoblasts differentiated into myotubes. We hypothesized that
PLD3 would localize to the ER or an ER-derived membrane
system during differentiation since, when overexpressed, it
localized to the ER in proliferating NIH3T3 cells (Fig. 2) and in
myoblasts (not shown). To determine if overexpressed PLD3
localized to the ER or SR in myotubes, C2C12 cells stably
expressing PLD3-myc were differentiated for 6 days. Unexpect-
edly, minimal co-localization was observed between PLD3 and the
ER/SR marker KDEL (Fig. 3A). However, there was a noticeable
association between the KDEL-positive ER/SR and PLD3-
positive vesicles, in that the great majority of the PLD3-positive
vesicles appeared to ‘‘decorate’’ the ER/SR membranes. Potential
co-localization was examined for PLD3 and cis-Golgi (using
GM130, Fig. 3B), peroxisomes (using 70-kDa peroxisomal
membrane protein (PMP70), Fig. 3C), developing T-tubules (using
Cav-3 as a marker, Fig. 3D), and secretory vesicles (using Rab 27,
Fig. 3E), but no significant association was observed. Other
organelle markers such as LC3A/B (autophagosomes) and 488-
transferrin (early endosomes) were also scored for co-localization
with PLD3, with no overlap observed (data not shown). Examining
the relationship between PLD3 and mitochondria was interesting,
however. Substantial co-localization was observed in myoblasts
undergoing fusion to myotubes between a subset of the PLD3
protein and restricted domains on the mitochondrial tubules (using
Cytochrome C to image the mitochondria, Fig. 3F, arrow, inset),
resembling the extent of overlap of mitochondrial and ER markers
observed at ‘‘mitochondrial-associated ER membranes’’ (MAMs).
Co-localization of PLD3 with mitochondria was also observed in
the myotubes (arrowheads). These data suggest that PLD3 resides
in the ER of non-fused, differentiating/fusing myoblasts before
they rearrange their ER membranes, in many cases in close
association with mitochondria. Our findings also suggest that
PLD3 localizes to ER-derived or highly specialized ER mem-
branes domains lacking KDEL antibody that are in close
association with typical ER once fusion takes place. One intriguing
possibility involves a recent report that described wrapping of ER
tubules around mitochondria tubules to mediate mitochondrial
fission [32]; these focal regions are known to be sites of lipid
transfer and synthesis, representing potential roles for PLD3.
Increased PLD3 expression enhances C2C12 myotube
formation
C2C12 myoblast populations stably expressing PLD3-myc, the
presumably catalytically-inactive and dominant-negative PLD3-
K418R-myc, or ER-targeted-mCherry (Clontech) as a negative
control were generated. Lysine 418 is a key amino acid in the
‘‘HKD’’ catalytic PLD superfamily motif, mutation of which to
Figure 1. PLD3 expression increases during myogenic differ-
entiation. (A) C2C12 cells were induced to differentiate for the
indicated periods of time and RNA extracts prepared using RNeasy
(Qiagen). Equal amounts of RNA were used as templates in quantitative
RT-PCR with PLD3- and GAPDH-specific primers used for amplification,
and performed in quadruplicate. The amount of PLD3 mRNA was
normalized to the amounts amplified for GAPDH. (B) C2C12 cells were
induced to differentiate for the indicated number of days and whole
cell lysates collected. Equal amounts of lysate protein, as determined by
Bradford reagent, were loaded onto SDS-polyacrylamide gels, and the
subsequent blot probed with anti-PLD3 and anti-GAPDH antibodies.
Representative blot of at least 3 independent experiments.
doi:10.1371/journal.pone.0033341.g001
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thus far [26]. After selection, the cell populations were induced to
differentiate for 6 days. Myoblasts expressing ER-mCherry visibly
formed myotubes by Day 3 (Fig. 4A) and continued to increase the
number and size of the myotubes through Day 6 (Fig. 4B), as
scored by a standard version of the fusion index (percentage of
[number of nuclei in myotubes with three or more nuclei] over
[total nuclei]). Using this fusion index, the PLD3-myc-overex-
pressing cells exhibited a significant increase in myoblast fusion by
day 5–6 compared to the ER-mCherry control cells, while the
PLD3-K418R-myc cells exhibited an initial lag in fusion and
trended towards lower fusion at day 6. Visually, many of the
typical PLD3-myc-overexpressing myotubes also appeared to be
larger than the typical ER-mCherry and PLD3-K418R-myc
myotubes (Fig. 4A), which was examined quantitatively by
determining fusion indices for generation of myotubes with 3–
10, 11–20, or .20 nuclei for each of the cell lines. With PLD3
overexpression, there were significantly more myotubes at day 5
with large numbers of nuclei per cell (and fewer with small
numbers of nuclei) than in the control myotubes (Fig. 5C), whereas
myotubes expressing the presumably inactive PLD3-K418 allele
were noteworthy for lacking myotubes with large numbers of
nuclei, while having many with only a few nuclei. Taken together,
expression of wild-type PLD3 appears to correlate with both an
increase in myotube size and an increase in the number of fusion
events.
Figure 2. The transmembrane domain directs PLD3 localization in proliferating cells. (A) Cartoon schematic of deletion mutants used in
this study. (B) NIH3T3 cells were transfected with PLD3-myc, PLD3-D1–60-myc, PLD3-D37–60-myc, or mito-PLD3-D1–37-myc and stained with anti-
myc and -KDEL antibodies. (C) NIH3T3 cells were transfected with PLD3-160-YFP, PLD3-37–60-YFP or PLD3 1–37-GFP and stained with anti-KDEL
antibodies. Imaging was performed using a Zeiss LSM 510 confocal microscope. Scale bar, 10 mm. Images are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0033341.g002
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33341Figure 3. PLD3 localizes to ER-associated vesicles in differentiating myotubes. C2C12 myoblasts expressing PLD3-myc were induced to
differentiate for 6 days on gelatin-coated coverslips. Following differentiation the cells were fixed and stained with anti-myc to visualize the
recombinant PLD3 protein and (A) anti-KDEL, (B) anti-GM130, (C) anti-PMP70, (D) anti-Cav3, (E) anti-Rab27 and (F) anti-Cytochrome C antibodies.
Scale bar, 10 mm. Myoblasts were identified as cells with a single nuclei, as opposed to the multi-nuclei myotubes. Arrows and arrowheads indicate
co-localization of PLD3 and mitochondria in myoblasts and myotubes, respectively. Blue, nuclear staining (DAPI); in other panels, asterisks denote
nuclei.
doi:10.1371/journal.pone.0033341.g003
Figure 4. Overexpression of PLD3 promotes myotube formation. (A) C2C12 cells expressing PLD3-myc, PLD3-K418R-myc or ER-mCherry
were induced to differentiate for 6 days on gelatin-coated coverslips, fixed in methanol, and stained with giemsa. Images are representative photos of
3 independent experiments. Scale bar, 200 mm. (B) Total fusion index analysis representing the percent of [nuclei in myotubes with 3 or more nuclei]/
[the total number of nuclei] in a field on days (D) 3–6 of differentiation. Ten fields were chosen at random for cell and nuclei counting from 3
independent experiments. *, P,0.05; **, P,0.01. (C) Fusion index analysis of myotubes with 3–10, 11–20 or .20 nuclei. (D, E) Western blot analysis of
MHC, CSQ, and m-cadherin in differentiating C2C12 cells expressing PLD3-myc, PLD3-K418R-myc or ER-mcherry.
doi:10.1371/journal.pone.0033341.g004
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with changes in rates of differentiation, temporal expression of the
myogenic markers myosin heavy chain (MHC) and calsequestrin
(CSQ), were examined by western blot analysis. Control ER-
mCherry, PLD3-myc, and PLD3-K418R-myc-expressing myo-
blasts were induced to differentiate for 6 days and whole cell
lysates were collected for western blot analysis. No significant
differences in the expression levels of calsequestrin (CSQ) (Fig. 4D)
or myogenin (not shown) were observed for the cell lines. There
was however, a slight delay in the increase in expression of myosin
heavy chain (MHC) in the PLD3-K418R-myc myoblasts. To
determine if the change in rates of fusion was due to altered
expression of fusion-related proteins, the expression levels of the
cell surface myofusion marker m-cadherin were also examined;
however, it did not appear significantly different among the three
cell populations (Fig. 4E).
Transient ER-stress with Thapsigargin increases PLD3
expression during differentiation
Transient ER-stress as induced using tunicamycin (TN) or
thapsigargin (TG) has been reported to exert a positive effect on
myofiber formation increase in culture [30], mimicking the action
of signals that drive differentiation in vivo. Given PLD3’s pattern
of localization in the ER, and the report that PLD3 senses
oxidative stress [28] which can impact differentiation events such
as myogenesis [29], we examined potential connections of PLD3
to ER stress in myotube formation. Transient ER-stress was
induced in C2C12 myoblasts using TN, TG, or Brefeldin-A (BFA)
in DMEM supplemented with 20%FBS for 30 minutes to 1 hour
immediately before initiating differentiation in DM supplemented
with 50 nM insulin. Cell lysates were collected on D0 (day of stress
and differentiation induction) and subsequent days for Western
blot analysis. PLD3 expression increased by day 2 in the TN- and
TG-stimulated myoblasts compared to the non-stimulated control
myoblasts, but not in the BFA-stimulated myoblasts (Fig. 5A). The
increase in PLD3 expression was sustained throughout the
remainder of the culture period, with a maximal PLD3 increase
observed of over 8-fold at day 4 for cells pre-treated with TG as
determined by densitometry. We next examined if the increase in
PLD3 was due simply to ER-stress or the combination of ER-stress
and differentiation: ER-stress was induced in C2C12 myoblasts
that were exposed to BFA, TN or TG in proliferation medium
Figure 5. Transient ER-stress increases PLD3 expression during myogenesis. (A) Western blot analysis of PLD3 in differentiating C2C12
myoblasts pre-treated for 30 min with thapsigargin (TG, 1 mM), tunicamycin (TN, 2 mg/ml), Brefeldin-A (BFA, 2 mM) or DMSO before differentiation for
the indicated periods of time. (B) Proliferating C2C12 myoblasts were treated with TG, TN, BFA, or DMSO for the indicated time followed by western
blot analysis for PLD3 expression. (C) Western blot analysis of HeLa cells pre-treated with TN without (D0) and with (subsequent days) serum
reduction for the indicated times. (D) Western blot analysis of C2C12 myoblasts pre-treated as shown with DMSO, TN, 1 mM DTT, or DTT and 10 mM
calcium ionophore A23187 before differentiation for 3 days. The PLD3 and GAPDH levels of expression were determined using Licor odyssey
software. The PLD3 level of expression was normalized to the level of GDPDH expression and is presented as fold-change with respect to the DMSO
control. Representatives of three independent experiments are shown.
doi:10.1371/journal.pone.0033341.g005
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differentiation. No induction of PLD3 expression was observed
(Fig. 5B), thus, ER stress does not induce PLD3 expression in itself,
but rather appears to amplify the induction triggered by
differentiation. To confirm the requirement for differentiation,
ER-stress was induced in HeLa cells as above that were then
cultured for up to 3 days in the reduced serum conditions that
stimulate C2C12 differentiation (however, the HeLa cells do not
undergo differentiation with this treatment); the HeLa cells were
also cultured short-term (up to 48 hours) in PM as above. Neither
mode of stress induction led the HeLa cells to upregulate PLD3
expression (Fig. 5C). These observations confirm that the increase
in PLD3 expression following ER stress in differentiating
myoblasts is due to the combined effects of ER-stress and
differentiation.
TN has been show to increase intracellular Ca
2+ levels and to
induce the unfolded protein response (UPR), which in turn causes
oxidative stress [33,34,35]. To determine if UPR induction and/or
increased Ca
2+ levels stimulate PLD3 expression during differen-
tiation, differentiating myoblasts were pretreated for 30 minutes
with the Ca
2+ ionophore A23187 to stimulate increased calcium
levels (data not shown), DTT to activate UPR, or both in
combination. The myoblasts were then induced to differentiate for
3 days followed by Western blot analysis to quantitate PLD3
expression. Compared to control myoblasts (Fig. 5D), no
significant increase in PLD3 expression was observed for
myoblasts pretreated with DTT (1.05-fold change in comparison
to control myoblasts, after normalization to the loading control
GAPDH) or the Ca
2+ ionophore A23187 alone (data not shown).
However, myoblasts pre-treated with both DTT and A23187
exhibited a 5-fold increase in PLD3 expression that was
comparable to that observed for TN, suggesting that it is the
combined effect of UPR and increased Ca
2+ levels that further up-
regulate PLD3 expression during differentiation.
Since there was an observable change in PLD3 expression in
differentiating myoblasts pre-treated with TN and TG, this raised
the issue of whether PLD3 might play a role involving altered
subcellular localization. To explore this possibility, C2C12
myotubes overexpressing PLD3-myc were allowed to differentiate
for 5 days on gelatin-coated coverslips. Once differentiated, the
myotubes were treated with BFA, TN, TG, amphotericin B (amph
B, which sequesters cholesterol from membranes, leading to the
collapse of the developing T-tubule system [36]) or wortmanin (to
inhibit PI3-Kinase activity, see [37]) for 4 hours, fixed, stained
with anti-myc and -KDEL antibodies, and imaged using confocal
microscopy. As initially shown in Fig. 3, PLD3-containing
membrane vesicles in control (DMSO-treated) cells were fre-
quently found in proximity to and decorated the ER but did not
precisely co-localize with the ER (Fig. 6A). PLD3 localization in
myotubes treated with BFA and TN looked largely similar to that
seen in the control cells, although a small increase in co-
localization was observed (Fig. 6B,C), and myotubes treated with
TG, amph B, and wortmanin showed significantly increased
amounts of co-localization (Fig. 6D–E). These findings suggest a
potential ER-connected role for PLD3 in myotubes for which ER
stress has been induced through any of a variety of mechanisms.
Discussion
Myogenesis is a highly complex, multi-tiered cell-cell fusion
event in which myoblasts reorganize much of their cellular
membranes and cytoskeleton during the processes that create
myotubes and eventually mature muscle fibers. We focused here
on PLD3, a poorly understood member of a well-studied family of
signaling enzyme, and began by showing that PLD3 protein is
upregulated during myoblast differentiation into myotubes,
consistent with the increase in PLD3 mRNA noted in a prior
microarray study [7]. As previously reported [21] and here in this
study, PLD3 overexpressed in proliferating cells localizes to the
ER. We have extended this observation to demonstrate that a
putative N-terminal transmembrane region is responsible for the
subcellular targeting of PLD3, and that a predicted N-terminal
secretory sequence is not required. The localization of PLD3 is
similar to that recently reported for PLD4 [38], the closest
mammalian homolog to PLD3. PLD4 localizes to the ER and
Golgi apparatus, presumably also via a transmembrane domain,
but it is found in immune cells rather than being expressed in a
wide variety of tissues. As with PLD3, no enzymatic activity has
been identified for PLD4, and its function is unknown.
Overexpression of PLD3 in differentiating myoblasts increased
myotube formation, and conversely, overexpression of a putatively
catalytically-inactive allele impeded myotube formation. This is
the first reported phenotype for PLD3 and suggests that it may be
necessary to look at models for differentiation to explore roles for
PLD3 rather than using standard proliferating cell lines. How
changes in PLD3 expression/activity alter myotube formation
remains unknown; however, the experiments with transient ER-
stress induced by TG and TN provide potential insight into the
connection.
One basis for how TN and TG affect PLD3 expression might be
through control of UPR activation, which in turn has been shown
to be involved in several types differentiation events, especially in
professional secretory cells [39,40,41]. Similarly, TG, which was
the strongest inducer of PLD3 expression, has been shown to
enhance osteoclast and osteoblast differentiation through activa-
tion of oxidative stress response and increase in expression of
osteoclast-specific genes [42,43]. PLD3 and oxidative stress have
previously been linked in a report that correlated levels of PLD3
expression to cellular sensitivity to oxidative stress [28].
Numerous attempts to knock down PLD3 and directly examine
its role in myogenic fusion were made using siRNA transfection
and lentiviral shRNA infection. All of the siRNA approaches were
found to be effective in model systems designed for validation of
the reagents, e.g. when COS7 cells were transfected with a PLD3
expression plasmid and co-transfected or infected with PLD3
siRNA and lentiviral shRNA, respectively (not shown). RNAi-
mediated knockdown of endogenous PLD3 in differentiating
myoblasts demonstrated encouraging findings including decreased
fusion and cell death. However, PLD3 protein was unexpectedly
found to be upregulated in the RNAi-targeted cells. These results
are not readily explained by off-target effects given the number of
different RNAi targeting sequences employed and the lack of
adverse effects in COS7 cells, which lead us to believe that PLD3
is critical for myoblast differentiation. Explanations for these
Figure 6. Thapsigargin increases PLD3 localization to perinuclear regions and the ER. C2C12 myoblasts overexpressing PLD3-myc were
induced to differentiate for 6 days on gelatin-coated coverslips. After differentiation the cells were treated with (A) DMSO, (B) BFA (C) TN, (D) TG, (E)
amphotericin B (25 mg/ml) or (F) wortmanin (10 mM) for 4 hours and then immunostained for anti-myc and anti-KDEL to visualize PLD3 and the ER,
respectively.
doi:10.1371/journal.pone.0033341.g006
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our observation above of a link between ER-stress responses and
increased PLD3 expression. It is possible that the RNAi-induced
transient decrease in PLD3 protein levels during differentiation led
to ER-stress and a strong induction of PLD3 expression/
translation and suppression of RNAi machinery, which is an
intriguing finding from which to direct future studies.
Taken together, our findings provide evidence to suggest that
PLD3 may be important or essential in myotube formation;
however, many questions concerning its mechanism of action
remain.
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